Abstract
MET amplification (amp) is rare in untreated metastatic colorectal cancer (mCRC), but cell-free DNA (cfDNA) analysis identifies it in 20% with anti-EGFR monoclonal antibody (mAb) refractory disease. We previously reported that cfDNA could detect focal versus non-focal MET amp in mCRC, and focal MET amp may be a better predictor of benefit from a MET inhibitor (Ann Oncol.2019; 30(suppl_5): abstr3022). However, the clinical and molecular landscape of MET amp mCRC is not well understood.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
